Adverse Skin Effects of Imatinib, a Tyrosine Kinase Inhibitor
Pretel-Irazabal M (1), Tuneu-Valls A (2), Ormaechea-Pérez N (2).
(1) Departamento de Dermatología, Clínica Universidad de Navarra, Pamplona, España.
(2) Departamento de Dermatología, Hospital de Donostia, San Sebastián, España.
Magazine: Actas Dermo-Sifiliográficas
Date: Sep 1, 2014Dermatology
Imatinib mesylate is a tyrosine kinase inhibitor that targets the BCR-ABL, c-kit, and PDGF (platelet-derived growth factor) receptors.
Imatinib is mainly indicated for chronic myeloid leukemia and gastrointestinal stromal tumors but is also prescribed by dermatologists for dermatofibrosarcoma protuberans, systemic sclerosis, and systemic mastocytosis, among other conditions. Most adverse effects are mild or moderate and therapy is generally well tolerated.
Adverse skin effects are very common and include nonspecific manifestations such as edema and maculopapular rashes or eruptions of diverse types (lichenoid or psoriasiform lesions, acute generalized exanthematic pustulosis, Stevens-Johnson syndrome, and more).
Identifying and properly treating these reactions can help optimize adherence to treatment and improve the prognosis of the underlying disease.
CITATION Actas Dermosifiliogr. 2014 Sep;105(7):655-62. doi: 10.1016/j.ad.2013.01.009. Epub 2013 Apr 30
tal vezLE INTERESE
The Clínica is the greater private hospital with technological equipment of Spain, all in a single center.
The professionals of the Clínica perform continuous research and training, always to the benefit of the patient.
Learn why we are different from other healthcare centers. Quality, speed, comfort and results.